Managed Care Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Kumamoto University
Mannosylated dendrimer/cyclodextrin conjugates improve gene delivery
August 16th, 2005
Mannosylated dendrimer/alpha-cyclodextrin conjugates improve gene delivery. "The purpose of this study is to evaluate in vitro and in vivo gene delivery efficiency of polyamidoamine (PAMAM) starburst dendrimer (generation 2, G2) conjugate with alpha-cyclodextrin (alpha-CDE conjugate (G2)) bearing mannose (Man-alpha-CDE conjugates) with the various degrees of substitution of the mannose moiety (DSM) as a novel non-viral vector in a variety of cells. Man-alpha-CDE conjugates (DSM 3.3 and 4.9) were found to have much higher gene transfer activity than dendrimer, a-CDE conjugate and Man-alpha-CDE conjugates (DSM 1.1 and 8.3) in various cells, which are independent of the...
Source: Managed Care Business Week (2005-08-16)
|
